Literature DB >> 6775804

Distribution and elimination of melphalan in rats and monkeys and distribution in tumors of mice bearing L1210 or P388 leukemias sensitive and resistant to this agent.

R K Brown, G Duncan, D L Hill.   

Abstract

Following iv injection, melphalan was eliminated monophasically from rat serum (half-life = 0.87 hour) and monkey serum (half-life = 1.9 hours) and in rat bile (half-life = 2.4 hours) and monkey urine (half-life = 1.3 hours). In rat bile and monkey urine, 2% and 20% of the dose, respectively, was excreted in 12 hours as unchanged melphalan. At each time of tissue assay (0.5-4 hours after injection), rat spleen contained less melphalan than serum, liver, or kidneys. The kidneys and bile of monkeys contained more melphalan that serum, liver, or spleen. Only a small amount of radioactivity from labeled melphalan appeared in the feces of monkeys. Melphalan reached higher concentrations in implants of P388 and L1210 leukemia cells sensitive to melphalan than in cell lines resistant to this drug. Furthermore, the amounts of radioactivity bound to macromolecules of the sensitive tumors were higher.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775804

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

Review 1.  Selective uptake and retention of anticancer agents by sensitive cells.

Authors:  D L Hill; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Intratumoral measurement and plasma pharmacokinetics of intravenously administered melphalan. Report of a patient with plasmacytoma.

Authors:  S Friberg; H Ehrsson; S Eksborg; C Carenfeldt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.